ReviewHepatobiliary surgery and nutrition2018
Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.
Review in Hepatobiliary surgery and nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 115 citations in OpenAlex.
- Exosomal microRNA-448 suppresses the malignant behaviors of liver cancer cells by targeting RAB7A and inhibiting glycolysis.Oncology letters · 2026Article
- Minimally invasive repeat liver resection in a patient with situs inversus totalis: report of a challenging case.Clinical journal of gastroenterology · 2026Article
- Pathological response ≥90% predicts survival in HCC treated with neoadjuvant loco-regional therapies: A retrospective cohort study.JHEP reports : innovation in hepatology · 2026Article
- Prognostic impact and predictive model for early non-curative recurrence after liver resection for hepatocellular carcinoma: a retrospective cohort study.International journal of surgery (London, England) · 2026Article
- Real-World Study of Post-Recurrence Treatment Strategies for Microvascular Invasion-Positive Hepatocellular Carcinoma After Curative Resection.Journal of hepatocellular carcinoma · 2026Article
- Hepatocellular Carcinoma With Small Bowel Metastasis and Intussusception: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.) · 2025Review
- Therapeutic efficacy of hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a propensity score matching study.World journal of surgical oncology · 2025Article
- Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation.Hepatology international · 2025Article
- Efficacy and safety of transcatheter arterial embolization combined with ablation and regorafenib for unresectable hepatocellular carcinoma patients failing first-line treatment: a real-world study.Journal of gastrointestinal oncology · 2025Article
- A novel nomogram based on machine learning predicting overall survival for hepatocellular carcinoma patients with dynamic α‑fetoprotein level changes after local resection.Oncology letters · 2025Article
- Article
- Chinese expert consensus on the diagnosis and treatment of hepatocellular carcinoma with microvascular invasion (2024 edition).Hepatobiliary surgery and nutrition · 2025Review
- Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.Liver cancer · 2025Article
- Construction and validation of a novel liver function-tumor burden-inflammation-nutrition (LTIN) score for HCC patients underwent hepatectomy.BMC cancer · 2025Article
- Radiofrequency ablation versus stereotactic body radiotherapy for recurrent hepatocellular carcinoma: a multicenter, propensity score matching analysis.BMC cancer · 2025Article
- Nomogram for predicting early cancer-related death due to recurrence after liver resection in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C: a multicenter study.BMC gastroenterology · 2025Article
- Hyper-Relapse Disease is a Special Pattern of Relapse of Hepatocellular Carcinoma After Curative Hepatectomy: A Retrospective Cohort Study.Journal of hepatocellular carcinoma · 2025Article
- Gene targets with therapeutic potential in hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024Article
- Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors at 11 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading cause of cancer-related death in the world. However, 40-70% patients eventually suffer from postoperative recurrence within 5 years. HCC recurrence after surgery severely affects prognosis of the patients. Nevertheless, there is an opportunity to improve patients' prognosis if doctors and researchers can recognize the importance of a standardized perioperative management and study it in clinical and pre-clinical settings. Hence, based on our own experience and published studies from other researchers, we develop this consensus regarding multidisciplinary management of locally recurrent and metastatic hepatocellular carcinoma after resection. This consensus consists of the entire course of recurrent hepatocellular carcinoma (RHCC) management, including prediction of recurrence, prevention, diagnosis, treatment and surveillance of RHCC. Consensus recommendations are presented with grades of evidences (Ia, Ib, IIa, IIb, III and IV), and strength of recommendations (A, B, C, D and E). We also develop a decision-making path for RHCC treatment, which can intuitively demonstrate the management for RHCC. It is hoped that we may make some effort to standardize the management of RHCC and ultimately understand how to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.